grant

tDCS to Decrease Opioid Relapse

Organization BUTLER HOSPITAL (PROVIDENCE, RI)Location PROVIDENCE, UNITED STATESPosted 30 Sept 2018Deadline 31 Dec 2026
NIHUS FederalResearch GrantFY2026AbstinenceActive Follow-upAcuteAddressAdjuvant TherapyAfter CareAfter-TreatmentAftercareAnodesBrainBrain Nervous SystemBuprenorphineCaringCathodesChemical DependenceClinicalConsumptionCritiquesDropoutDrug AddictionDrug DependenceDrug DependencyDrug usageDrugsDysfunctionEncephalonFunctional MRIFunctional Magnetic Resonance ImagingFunctional disorderHeroin UsersImmediate MemoryImpulsivityInformal Social ControlInterventionInvestigatorsLeftMeasuresMedicationModelingMotivationNerve CellsNerve UnitNeural CellNeurocyteNeuronsOpiate userOpiatesOpioidOpioid drug userOutcomePWUOParticipantPersonsPharmaceutical PreparationsPhasePhysiopathologyPopulationPrefrontal CortexRandomizedRelapseResearch PersonnelResearchersRestRewardsSafetySelf RegulationShort-Term MemorySubstance Use DisorderSystemTechniquesTestingTreatment FailureTreatment PeriodValidationWithdrawal SymptomWorkactive followupaddictionaddictive disorderadjuvant treatmentbehavior measurementbehavioral measurebehavioral measurementbuprenorphine treatmentclinical careclinical efficacycognitive controlcompare interventioncomparison interventioncravingcue reactivitydrug usedrug/agentfMRIfMRI scanfollow upfollow-upfollowed upfollowupfunctional MRI scanfunctional magnetic resonance imaging scanhigh riskneuralneural controlneural mechanismneural regulationneurobehavioralneuromechanismneuromodulationneuromodulatoryneuronalneuroregulationnon-invasive brain stimulationopiate consumptionopiate crisisopiate drug useopiate intakeopiate useopiate use disorderopioid consumptionopioid crisisopioid drug useopioid epidemicopioid intakeopioid useopioid use disorderopioid useroverdose riskpathophysiologypeople who use opioidspersons who use opioidsportabilitypost treatmentrandomisationrandomizationrandomly assignedresponseresponse to therapyresponse to treatmentsubstance use and disordertherapeutic responsetherapy failuretherapy responsetranscranial direct current stimulationtreatment daystreatment durationtreatment responsetreatment responsivenessvalidationsworking memory
Sign up free to applyApply link · pipeline · email alerts
— or —

Get email alerts for similar roles

Weekly digest · no password needed · unsubscribe any time

Full Description

Buprenorphine has emerged as a leading treatment for opioid use disorder (OUD), but recipients have high
early relapse rates likely due to varying degrees of dysfunction within craving and cognitive control neuronal

networks. Transcranial direct current stimulation (tDCS) may have promise as adjuvant treatment for

buprenorphine initiators because considerable work on addictive substances suggests treatment targeted at the

dorsolateral prefrontal cortex (DLPFC; region involved in self-regulation) may reduce craving and drug

consumption. We will measure behavioral and brain responses following tDCS stimulation to the DLPFC

delivered during cognitive control network (CCN) priming. Participants in their first week of prescribed

buprenorphine will be assessed twice using FMRI, once prior to tDCS+CCN priming and again at the

completion of 5 sessions of tDCS+CCN priming (one week later). Task-based and resting state functional

connectivity will be used to examine networks associated with craving (CR) and cognitive control. In the UG3

phase (n=60), FMRI will provide validation of expected changes in these networks following tDCS stimulation.

Go/no go criteria for the UH3 phase will be demonstration of greater FMRI change in any node of the CR or

CCN networks AND greater change in subjective craving measured prior to (outside FMRI scan) or during an

FMRI cue reactivity task following the tDCS+CCN priming intervention compared to sham tDCS+CCN

priming. In the UH3 phase (n=100), we will perform a larger RCT (vs. sham control) to address long-term

neurobehavioral outcomes, including opioid relapse, craving, and sustained fMRI changes. Because tDCS is

safe, inexpensive and portable, if this intervention provides FMRI validation of targeted brain effects and

produces clinical response, it could have great impact augmenting the care of persons entering buprenorphine

treatment, a population at high risk for treatment failure.

Grant Number: 5UH3DA047793-05
NIH Institute/Center: NIH

Principal Investigator: Ana Abrantes

Sign up free to get the apply link, save to pipeline, and set email alerts.

Sign up free →

Agency Plan

7-day free trial

Unlock procurement & grants

Upgrade to access active tenders from World Bank, UNDP, ADB and more — with email alerts and pipeline tracking.

$29.99 / month

  • 🔔Email alerts for new matching tenders
  • 🗂️Track tenders in your pipeline
  • 💰Filter by contract value
  • 📥Export results to CSV
  • 📌Save searches with one click
Start 7-day free trial →